Find Paid Research Studies in Beaverton, Oregon

Browse Locations ... United States» ... Oregon» ... Beaverton

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified May 2013
Study of Dupilumab (REGN668/ SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Online Parent Training for Children With Behavior Disorders

Conditions: Parenting; Delinquency
Intervention: Behavioral: Parenting Wisely
Sponsors: Family Works Incorporated; Family Works Incorporated; Oregon Research Institute
Recruiting - verified May 2013
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Conditions: Peripheral Arterial Disease; Diabetic Foot
Interventions: Biological: 3 x 10^6 cells; Biological: 10 x 10^6 cells; Biological: 30 x 10^6 cells; Biological: 100 x 10^6 cells
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Condition: Influenza
Interventions: Biological: Trivalent influenza vaccine virus; Biological: Placebo
Sponsors: MedImmune LLC; MedImmune LLC; AstraZeneca, PLC
Not yet recruiting - verified May 2013
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study

Condition: Breast Augmentation, Reconstruction, or Revision of Breast Augmentation or Reconstruction
Intervention: Device: Anatomically shaped silicone gel-filled breast implants
Sponsors: Allergan Medical; Allergan Medical
Recruiting - verified May 2013
Community Dissemination of Tai Ji Quan

Condition: Older Adults at Risk of Falling
Intervention: Behavioral: Tai Ji Quan
Sponsors: Oregon Research Institute; Oregon Research Institute
Recruiting - verified May 2013
A Study of IMC-1 In Patients With Fibromyalgia

Conditions: Fibromyalgia; Chronic Pain; Myofascial Pain
Intervention: Drug: IMC-1
Sponsors: Innovative Med Concepts, LLC; Innovative Med Concepts, LLC
Recruiting - verified May 2013
Angel™ Catheter Early Feasibility Clinical Study

Conditions: Pulmonary Embolism; Deep Vein Thrombosis; Venous Thromboembolism
Intervention: Device: Angel™ Catheter
Sponsors: BiO2 Medical; BiO2 Medical
Not yet recruiting - verified May 2013
Clinical and Genetic Characterization of Individuals With Achromatopsia

Condition: Achromatopsia
Intervention:
Sponsors: Applied Genetic Technologies Corp; Applied Genetic Technologies Corp
Not yet recruiting - verified May 2013
Web-based Parenting Intervention for Mothers of Infants At-Risk for Maltreatment (Baby-Net)

Condition: Parenting
Interventions: Behavioral: Baby-Net; Behavioral: Developmental Awareness Skills
Sponsors: Oregon Research Institute; Oregon Research Institute
Recruiting - verified May 2013
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Condition: Generalized Anxiety Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified April 2013
Examining Bladder Control Using Mindful Based Approach

Condition: Urinary Urgency Incontinence
Intervention: Other: Mindfulness Based Stress Reduction Course
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified April 2013
Evaluation of an School-based Alcohol Prevention Program for Middle School Students

Conditions: Alcohol-related Disorders; Drinking and Driving; Neurological Impairment
Intervention: Behavioral: Click City®: Alcohol
Sponsors: Oregon Research Institute; Oregon Research Institute; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified May 2013
The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
Applying the Use of Motivational Tools to Auditory Rehabilitation

Conditions: Hearing Loss; Hearing Aids; Rehabilitation; Motivational Interviewing
Interventions: Behavioral: Standard-of-Care; Behavioral: Treatment
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified May 2013
Randomized Endo-Vein Graft Prospective

Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified May 2013
12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia

Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified May 2013
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy

Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013
A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

Condition: Basal Cell Carcinoma
Interventions: Drug: vismodegib; Drug: vismodegib; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

Condition: Phenylketonuria
Intervention: Drug: BMN 165
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2013
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

Condition: Growth Hormone Deficiency
Interventions: Drug: TV-1106; Drug: Recombinant human growth hormone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Growth and Tolerance of Infants Fed Infant Formulas

Condition: Growth and Tolerance
Interventions: Other: Control Formula; Other: Experimental Formula 1; Other: Experimental Formula 2; Other: Human Milk
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified May 2013
Clinical Trial Nuedexta in Subjects With ALS

Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: Nuedexta; Drug: Matching Placebo
Sponsors: Center for Neurologic Study, La Jolla, California,; Center for Neurologic Study, La Jolla, California,; ALS Association; State University of New York - Upstate Medical University
Recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Improving Syncope Risk Stratification in Older Adults

Condition: Syncope
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Institutes of Health (NIH)
Recruiting - verified April 2013
A Study of LY2940094 in Participants With Alcohol Dependency

Condition: Alcoholism
Interventions: Drug: LY2940094; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified April 2013
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Conditions: Ischemic Stroke; Malignant Edema
Intervention: Drug: RP-1127 (Glyburide for Injection)
Sponsors: Remedy Pharmaceuticals, Inc.; Remedy Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Conditions: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
Intervention: Drug: GS-9973
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Human Insulin NPH
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2013
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Condition: Asthma
Interventions: Drug: FS Spiromax; Drug: Fluticasone propionate Spiromax; Drug: Advair Diskus
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified May 2013
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified May 2013
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial

Condition: Aneurysm
Interventions: Drug: Doxycycline; Drug: Placebo
Sponsors: University of Maryland; University of Maryland; National Institute on Aging (NIA)
Recruiting - verified May 2013
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate plus degarelix; Drug: Degarelix
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Janssen Pharmaceuticals; OHSU Knight Cancer Institute; Cancer Institute of New Jersey; NorthShore University HealthSystem Research Institute; Duke University; Feinberg School of Medicine, Northwestern University; Sidney Kimmel Comprehensive Cancer Center; University of North Carolina; Wayne State University
Recruiting - verified May 2013
Cervical Preparation Before Dilation and Evacuation

Condition: Abortion, Induced
Interventions: Other: Mifepristone; Drug: misoprostol; Device: Osmotic dilators; Other: placebo; Other: placebo
Sponsors: Planned Parenthood League of Massachusetts; Planned Parenthood League of Massachusetts; Society of Family Planning
Recruiting - verified May 2013
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
Early Diagnosis of Pulmonary Nodules

Conditions: Precancerous Conditions; Carcinoma
Intervention:
Sponsors: Integrated Diagnostics; Integrated Diagnostics
Recruiting - verified April 2013
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empaglifozin placebo + Linagliptin placebo; Drug: Empagliflozin + Linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
Video Impact on Neulasta Education

Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (P07771/MK-3222-011)

Condition: Plaque Psoriasis
Interventions: Drug: MK-3222 200 mg; Drug: MK-3222 100 mg; Drug: MK-3222 Placebo; Drug: Etanercept Placebo; Drug: Etanercept 50 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Condition: Reduction of Hypertrophic Skin Scarring
Interventions: Drug: PF-06473871; Drug: PF-06473871
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: BI 207127; Drug: Faldaprevir (BI 201335)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: BMS-936558; Drug: Dacarbazine; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis Participants

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Moderate to Severe Rheumatoid Arthritis Study

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579 AM4)

Condition: Fungal Infections
Intervention: Drug: Posaconazole oral suspension
Sponsors: Merck; Merck
Recruiting - verified April 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients

Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg); Drug: HM10460A (135 μg/kg); Drug: HM10460A (270 μg/kg); Drug: Pegfilgrastim 6mg
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified May 2013
Non-exudative Age-related Macular Degeneration

Condition: Non-exudative Age-related Macular Degeneration
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2013
NOLAN: Naproxen or Loratadine and Neulasta

Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen; Drug: Loratadine
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Neovascular Age-related Macular Degeneration

Condition: Neovascular Age-related Macular Degeneration
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2013
A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib; Drug: Methotrexate; Drug: Placebo; Drug: Folic Acid
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

Condition: Hodgkin Disease
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387; Drug: Crizotinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013
Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Matching placebo to MK-3012; Drug: Glimepiride; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Conditions: Medulloblastoma, Childhood; Rhabdomyosarcoma
Interventions: Drug: LY2940680; Drug: LY2940680
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Phase 2 Study of TD-9855 to Treat Fibromyalgia

Condition: Fibromyalgia
Interventions: Drug: TD-9855 Group 1; Drug: TD-9855 Group 2; Drug: Placebo
Sponsors: Theravance, Inc.; Theravance, Inc.
Recruiting - verified May 2013
Adult Attention Deficit Hyperactivity Disorder

Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (Mcg) , FF/VI 100/25 Mcg, and FF 100 Mcg in Adults and Adolescents With Persistent Asthma.

Condition: Asthma
Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg; Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg; Drug: Fluticasone Furoate 100 mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Bilogicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Investigation of Sacroiliac Fusion Treatment (INSITE)

Conditions: Degenerative Sacroiliitis; Sacroiliac Joint Disruption
Interventions: Device: iFuse Implant System; Other: Non-surgical management
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Recruiting - verified May 2013
Effectiveness Trial of a Dissonance-Based Obesity Prevention Program

Conditions: Obesity; Weight Gain; Eating Disorders
Interventions: Behavioral: Healthy Weight; Behavioral: Project Health
Sponsors: Oregon Research Institute; Oregon Research Institute
Recruiting - verified April 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls

Condition: Transplantation, Cytomegalovirus Infections
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Multiple Ascending Dose

Condition: Hepatocellular Carcinoma
Interventions: Biological: BMS-936558 (Anti-PD-1 antibody); Biological: BMS-936558 (Anti-PD-1 antibody)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified May 2013
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: OMP-59R5; Drug: Gemcitabine; Drug: Placebo; Drug: Nab-Paclitaxel
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.
Recruiting - verified March 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Condition: Asthma
Interventions: Drug: Tiotropium low dose QD; Drug: Tiotropium high dose QD; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2013
A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012 AM2)

Condition: Asthma
Interventions: Drug: MK-1029 10 mg; Drug: MK-1029 30 mg; Drug: MK-1029 150 mg; Drug: Montelukast 10 mg; Drug: Placebo; Drug: MK-1029 1 mg or 3 mg; Drug: Montelukast 10 mg + MK-1029
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified May 2013
An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis

Conditions: Primary Myelofibrosis; Post Polycythemia Vera Fibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Intervention: Drug: asparaginase Erwinia chrysanthemi
Sponsors: EUSA Pharma (US), Inc.; EUSA Pharma (US), Inc.
Recruiting - verified May 2013
National Parkinson Foundation Quality Improvement Initiative

Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013
STorz Against Glidescope Effectiveness

Condition: Difficult Airway
Interventions: Device: C-MAC; Device: Glidescope
Sponsors: Oregon Health and Science University; Oregon Health and Science University; University of Iowa; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Conditions: Advanced Melanoma; Metastatic Melanoma
Intervention: Biological: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

Condition: Juvenile Idiopathic Arthritis Associated Uveitis
Intervention: Drug: Tocilizumab
Sponsors: Oregon Health and Science University; Eric B. Suhler; Genentech
Not yet recruiting - verified May 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis

Condition: Multiple Sclerosis
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2013
Eisenmenger Quality Enhancement Research Initiative

Condition: Eisenmenger
Intervention: Other: Management
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

Condition: Anaemia
Interventions: Drug: GSK1278863; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified April 2013
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Age-Related Maculopathy
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714 AM2)

Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Dinaciclib; Drug: Ofatumumab
Sponsors: Merck; Merck
Recruiting - verified May 2013
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Dose-ranging Study of Fluticasone Furoate (FF)

Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)

Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Pediatric Arthritis Study of Certolizumab Pegol

Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

Condition: Juvenile Idiopathic Arthritis
Interventions: Behavioral: Web-based coping skills training; Behavioral: Online disease education
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013
MRI Assessment of Leukemia Response to Therapy

Condition: Acute Myelogenous Leukemia
Intervention: Device: 3T Siemens TIM Trio whole-body system
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute
Recruiting - verified April 2013
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma

Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Childhood Alveolar Soft-part Sarcoma; Childhood Angiosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Childhood Epithelioid Hemangioendothelioma; Childhood Epithelioid Sarcoma; Childhood Fibrosarcoma; Childhood Leiomyosarcoma; Childhood Liposarcoma; Childhood Malignant Hemangiopericytoma; Childhood Malignant Mesenchymoma; Childhood Neurofibrosarcoma; Childhood Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride; Drug: pazopanib hydrochloride; Other: placebo; Other: laboratory biomarker analysis
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; GlaxoSmithKline
Recruiting - verified May 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Cervicogenic Headache Dose-Response

Condition: Cervicogenic Headache
Interventions: Other: Spinal Manipulation; Other: Light Massage
Sponsors: University of Western States; University of Western States; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Condition: Lung Injury, Acute
Interventions: Drug: Dose 1 GSK2586881; Drug: Dose 2 GSK2586881; Drug: Dose 3 GSK2586881; Drug: Dose 4 GSK2586881; Drug: Placebo (saline)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013
Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi; Bristol-Myers Squibb; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Recruiting - verified May 2013
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Conditions: Usher Syndrome; Retinitis Pigmentosa
Intervention: Genetic: UshStat
Sponsors: Oxford BioMedica; Oxford BioMedica
Recruiting - verified May 2013
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)

Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Drug: Placebo Metered Dose Inhaler (MDI); Drug: Placebo Dry Powder Inhaler (DPI)
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

Condition: Reduction in Severity of Skin Scarring
Intervention: Drug: EXC 001
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome
Interventions: Drug: 250 mg LX1033 tablets; Drug: Placebo tablet
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified April 2013
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2013
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2013
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified May 2013
Vest Prevention of Early Sudden Death Trial and VEST Registry

Conditions: Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation
Intervention: Device: wearable defibrillator
Sponsors: University of California, San Francisco; University of California, San Francisco; Zoll Medical Corporation
Recruiting - verified April 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity

Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Dasatinib
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; Bristol-Myers Squibb
Recruiting - verified May 2013
A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified May 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013
A Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Subjects With Hemophilia A Or B

Condition: Hemophilia A
Interventions: Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions: Infection; Hypertension; Anesthesia; Pain; Reflux
Intervention: Drug: Ampicillin
Sponsors: Duke University; Daniel Benjamin; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); The EMMES Corporation
Recruiting - verified May 2013
Blood Tests to Study Injury Severity and Outcome in Traumatic Brain Injury Patients

Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Hydrogel Endovascular Aneurysm Treatment Trial

Condition: Cerebral Aneurysm
Interventions: Device: HydroCoil Embolic System; Device: Control (bare platinum coils)
Sponsors: Northwestern University; Northwestern University; MicroVention, Inc
Recruiting - verified May 2013
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Proteomic Assessment of Preterm Birth

Condition: Preterm Birth
Intervention:
Sponsors: Sera Prognostics, Inc.; Sera Prognostics, Inc.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma USA Inc
Recruiting - verified May 2013
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: Real Acupressure Band; Procedure: Placebo Acupressure Band
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified May 2012
Patients Treated for SCID (1968-2010)

Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients

Condition: Colon Cancer
Intervention:
Sponsors: Oregon State University; Oregon State University; Oregon Health and Science University; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure

Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome; Respiratory Failure
Interventions: Drug: IV Ganciclovir and Valganciclovir; Drug: Placebo
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI); Genentech
Recruiting - verified April 2013
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; German Low Grade Lymphoma Study Group; Institute of Cancer Research, United Kingdom
Recruiting - verified May 2013
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013
Advanced Imaging for Glaucoma Study

Condition: Glaucoma
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Eye Institute (NEI)
Recruiting - verified May 2013
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time

Conditions: Oropharyngeal Cancer; Human Papillomavirus
Intervention:
Sponsors: Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Mount Sinai School of Medicine; Oregon Health and Science University; Dana-Farber Cancer Institute; Johns Hopkins Hospital (JHH)
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Carcinoma, Thymic
Interventions: Drug: AZD; Drug: MK-2206; Drug: Lapatinib; Drug: Erlotinib; Drug: Sunitinib; Procedure: Molecular Profiling
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2012
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013
AMES Treatment of the Impaired Leg in Chronic Stroke Patients

Conditions: Stroke; Cerebrovascular Accident; Hemiparesis
Intervention: Device: AMES- Leg therapy
Sponsors: AMES Technology; AMES Technology; Oregon Health and Science University; Northwestern University; Rehabilitation Institute of Chicago; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Internet-Based Sexual Health Education for Middle School Native American Youth

Conditions: Sexually Transmitted Diseases; Pregnancy; HIV Infections
Interventions: Behavioral: HIV, STI and Pregnancy Prevention Curriculum; Behavioral: Control Curricula
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Alaska Native Tribal Health Consortium; Inter Tribal Council of Arizona; Northwest Portland Area Indian Health Board
Recruiting - verified May 2013
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Fondazione Italiana Linfomi ONLUS
Recruiting - verified May 2013
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013
Abatacept in the Treatment of Uveitis

Condition: Uveitis
Intervention: Drug: Abatacept
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Bristol-Myers Squibb
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

Condition: Prostate Cancer Prevention
Interventions: Drug: sulforaphane glucosinolate capsules; Dietary Supplement: Gelatin capsule containing cellulose and magnesium stearate
Sponsors: Portland VA Medical Center; Portland VA Medical Center; National Cancer Institute (NCI); Oregon State University; OHSU Knight Cancer Institute
Recruiting - verified April 2013
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2013
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Condition: Non-Small-Cell Lung Carcinoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

Condition: Corneal Opacity
Intervention: Drug: OCT-guided laser phototherapeutic keratectomy
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Eye Institute (NEI)
Recruiting - verified May 2013
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified April 2013
Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene

Condition: D842-related Mutant GIST
Intervention: Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
Sponsors: Arog Pharmaceuticals LLC; Arog Pharmaceuticals LLC
Recruiting - verified May 2013
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy

Conditions: Adenocarcinoma of the Prostate; Castrate Resistant Prostate Cancer; Recurrent Prostate Cancer
Interventions: Drug: docetaxel; Procedure: prostate biopsy; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Drug: phenelzine sulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2013
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: IMGN901; Drug: Carboplatin and Etoposide
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified April 2013
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013
A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Condition: Neoplasms, Breast
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Growth of Infants Fed an Extensively Hydrolyzed Infant Formula

Condition: Growth
Interventions: Other: Extensively hydrolyzed whey infant formula; Other: Extensively hydrolyzed casein infant formula
Sponsors: Nestlé; Nestlé
Recruiting - verified May 2013
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Children's Hospital Boston; University of California, San Francisco; Ann & Robert H Lurie Children's Hospital of Chicago; Children's Healthcare of Atlanta; Children's Hospital Colorado; Children's Hospital Los Angeles; Children's Hospital of Michigan; Children's Hospitals and Clinics of Minnesota; Cook Children's Medical Center; Doernbecher Children's Hospital; Duke University; Johns Hopkins University; Memorial Sloan-Kettering Cancer Center; Miami Children's Hospital; New York University; Penn State Hershey Medical Center; Seattle Children's; University of Louisville; University of Mississippi Medical Center; UT Southwestern Medical Center; Washington University Medical Center
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)

Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Condition: Smallpox
Interventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: Placebo
Sponsors: Bavarian Nordic; Bavarian Nordic
Recruiting - verified May 2013
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Condition: Neoplasms Malignant
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2013
A Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Carboplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

Condition: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution
Sponsors: University of Pennsylvania; John Kempen
Recruiting - verified April 2013
Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: lipoic acid and fish oil concentrate
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib; Drug: Erlotinib
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Strategic Timing of Antiretroviral Treatment

Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013
Progesterone for the Treatment of Traumatic Brain Injury

Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); BSN Medical Inc; Genentech; Covidien; BayerHealthcare; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2013
The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

Condition: Atherosclerosis
Intervention: Dietary Supplement: Crossover of R-alpha lipoic acid and placebo
Sponsors: Oregon State University; Oregon State University; Oregon Health and Science University; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013
Lipoic Acid and Prevention of Heart Disease

Condition: Atherosclerosis
Interventions: Dietary Supplement: R-alpha lipoic acid; Dietary Supplement: Placebo
Sponsors: Oregon State University; Oregon State University; Oregon Health and Science University; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease (The Long-term Oxygen Treatment Trial [LOTT])

Condition: Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: Supplemental oxygen therapy
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Centers for Medicare and Medicaid Services
Recruiting - verified May 2013
Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability

Condition: Hip Osteoarthritis
Interventions: Behavioral: Structured exercise program; Behavioral: Waitlist, delayed intervention
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2013
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013
Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions: Transthyretin Mutations; Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
International Hernia Mesh Registry

Condition: Hernia
Intervention:
Sponsors: Ethicon, Inc.; Ethicon, Inc.
Recruiting - verified April 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Statin Therapy Versus Placebo Prior to Prostatectomy

Conditions: Cancer; Prostate
Interventions: Drug: Simvastatin; Other: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Oregon Health and Science University
Recruiting - verified May 2013
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Condition: Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.

Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Condition: Hemophilia A
Interventions: Biological: Moroctocog alfa (AF-CC); Biological: Moroctocog alfa (AF-CC)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography

Condition: Cataract
Intervention: Device: OCT measurements
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Eye Institute (NEI)
Recruiting - verified May 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Advanced Gastric Cancer; Advanced/Metastatic Non-small Cell Lung Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Repository for Inherited Eye Diseases

Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2012
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

Condition: Kidney Transplantation
Interventions: Drug: Tacrolimus; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
Treating Patients With High-Grade Glioma With IA Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate

Conditions: Brain and Central Nervous System Tumors; Thrombocytopenia
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Etoposide phosphate; Drug: Etoposide; Drug: Sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013

Find Paid Research Studies in Beaverton, Oregon

Welcome to Paid Research Studies.